Anand Jillella

Section Chief

  • 1220 Citations
  • 17 h-Index
1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Anand Jillella is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Multiple Myeloma Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Stem Cells Medicine & Life Sciences
Acute Promyelocytic Leukemia Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1990 2019

  • 1220 Citations
  • 17 h-Index
  • 50 Article
  • 9 Letter
  • 2 Review article
  • 1 Comment/debate

Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA

Bolds, S. L., Hassan, S. M. K., Caprara, C. R., Debragga, S., Simon, K. S., Karkhanis, P., Gandhi, A., Jillella, A. P. & Kota, V. K., Jan 1 2019, In : Hematology Reports. 11, 2, p. 28-29 2 p., 7896.

Research output: Contribution to journalArticle

Open Access
Acute Promyelocytic Leukemia
Tretinoin
Clinical Protocols
Formularies
Directories
33 Citations (Scopus)

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Stein, E. M., Walter, R. B., Erba, H. P., Fathi, A. T., Advani, A. S., Lancet, J. E., Ravandi, F., Kovacsovics, T., DeAngelo, D. J., Bixby, D., Faderl, S., Jillella, A. P., Ho, P. A., O'Meara, M. M., Zhao, B., Biddle-Snead, C. & Stein, A. S., Jan 25 2018, In : Blood. 131, 4, p. 387-396 10 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Patient treatment
Pharmacokinetics
Platelets
Dimers
12 Citations (Scopus)

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Fathi, A. T., Erba, H. P., Lancet, J. E., Stein, E. M., Ravandi, F., Faderl, S., Walter, R. B., Advani, A. S., DeAngelo, D. J., Kovacsovics, T. J., Jillella, A., Bixby, D., Levy, M. Y., O’Meara, M. M., Ho, P. A., Voellinger, J. & Stein, A. S., Sep 13 2018, In : Blood. 132, 11, p. 1125-1133 9 p.

Research output: Contribution to journalArticle

Proxy
Acute Myeloid Leukemia
decitabine
Cytogenetics
Toxicity
17 Citations (Scopus)

Ruxolitinib: A steroid sparing agent in chronic graft-versus-host disease

Khoury, H. J., Langston, A. A., Kota, V., Wilkinson, J. A., Pusic, I., Jillella, A., Bauer, S., Kim, A. S., Roberts, D., Al-Kadhimi, Z., Bodo, I., Winton, E., Arellano, M. & Dipersio, J. F., Jul 1 2018, In : Bone marrow transplantation. 53, 7, p. 826-831 6 p.

Research output: Contribution to journalArticle

Graft vs Host Disease
Steroids
Janus Kinases
Allografts
Lung
7 Citations (Scopus)
Acute Promyelocytic Leukemia
Leukemia
Mortality
Population
Guidelines